# Phase 1/2 colorectal cancer trials recruiting: 125 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 125 trials in phase 1/2 for colorectal cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 colorectal cancer trials: 125 rows for $6.25, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/colorectal-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 125
- Recruiting or not yet: 125
- Read on: November 19, 2026

## Trials

The 25 newest of 125, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07947134 | A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours | GlaxoSmithKline | Phase 1/2 | Not yet recruiting | Solid Tumours | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07947134) |
| November 17, 2026 | NCT07941362 | 177Lu-ACT319 in FAP Expressing Solid Tumors | Actithera INC. | Phase 1/2 | Not yet recruiting | FAP-expressing Solid Tumors, Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Carcinoma (BTC) | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07941362) |
| November 16, 2026 | NCT07939815 | A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Bristol-Myers Squibb | Phase 1/2 | Not yet recruiting | Advanced Solid Malignancies | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939815) |
| November 3, 2026 | NCT07912593 | A KRAS Inhibitor in Participants With Advanced Solid Tumors | Ensem Therapeutics | Phase 1/2 | Recruiting | Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer... | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912593) |
| October 27, 2026 | NCT07897227 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors. | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Gastric Cancer (GC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897227) |
| October 14, 2026 | NCT07873450 | SumMET: Study of \[225Ac\]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET | Full-Life Technologies UK Limited | Phase 1/2 | Recruiting | Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer, Cholangiocarcinoma | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873450) |
| October 7, 2026 | NCT07863024 | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Advanced Solid Tumors | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863024) |
| September 28, 2026 | NCT07844187 | TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Phase 1/2 | Not yet recruiting | Colorectal Neoplasms | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844187) |
| September 8, 2026 | NCT07807800 | A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer... | D. E. Shaw Research, LLC | Phase 1/2 | Not yet recruiting | Metastatic Colorectal Cancer (CRC) | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807800) |
| September 4, 2026 | NCT07805551 | A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | CRC, Colorectal Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805551) |
| August 28, 2026 | NCT07791758 | A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Recruiting | Metastatic Colorectal Carcinoma | 369 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791758) |
| August 27, 2026 | NCT07790510 | HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer | Haisco Pharmaceutical Group Co., Ltd. | Phase 1/2 | Recruiting | Metastatic Colorectal Cancer (CRC) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790510) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 6, 2026 | NCT07750041 | A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Unresectable Advanced or Metastatic Colorectal Cancer | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750041) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 4, 2026 | NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | Iovance Biotherapeutics, Inc. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and... | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743723) |
| July 9, 2026 | NCT07693751 | A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer | SOTIO Biotech a.s. | Phase 1/2 | Recruiting | Colorectal Cancer (Locally Advanced or Metastatic) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07693751) |
| July 6, 2026 | NCT07683403 | Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer | Fudan University | Phase 1/2 | Not yet recruiting | Colorectal Cancer (CRC) | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683403) |
| June 26, 2026 | NCT07670312 | Evaluation of XYA02 in Patients With Advanced Solid Tumors | XYone Therapeutics, Inc | Phase 1/2 | Recruiting | MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ... | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670312) |
| June 17, 2026 | NCT07653685 | A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed... | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Colorectal Cancer | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07653685) |
| June 9, 2026 | NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors | VM Discovery, Inc. | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer... | 111 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636785) |
| June 5, 2026 | NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | Blueprint Medicines Corporation | Phase 1/2 | Recruiting | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629960) |
| May 18, 2026 | NCT07591597 | A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus... | National Cancer Center Hospital East | Phase 1/2 | Not yet recruiting | Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07591597) |
| May 15, 2026 | NCT07589517 | Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer | Beijing Biotech | Phase 1/2 | Recruiting | Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589517) |
| April 27, 2026 | NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | BOE Technology Group Co., Ltd. | Phase 1/2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551778) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 4 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 3 |
| National Cancer Institute (NCI) | 3 |
| Cancer Research UK | 3 |
| Essen Biotech | 3 |
| Jacobio Pharmaceuticals Co., Ltd. | 2 |
| Fudan University | 2 |
| Roswell Park Cancer Institute | 2 |
| [Betta Pharmaceuticals Co., Ltd.](https://specstream.ai/data/clinical-trials/company/betta-pharmaceuticals-co-ltd) | 2 |
| M.D. Anderson Cancer Center | 2 |
| Genfleet Therapeutics (Shanghai) Inc. | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| [BioNTech SE](https://specstream.ai/data/clinical-trials/company/biontech-se) | 2 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 2 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 2 |
| Parabilis Medicines, Inc. | 1 |
| One-carbon Therapeutics AB | 1 |
| IDEAYA Biosciences | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 |
| QuantumLeap Healthcare Collaborative | 1 |
| Twinpig Biolab, Inc. | 1 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 1 |
| Arvinas Inc. | 1 |
| MBrace Therapeutics | 1 |
| PMV Pharmaceuticals, Inc | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 65 |
| China | 34 |
| Spain | 20 |
| Australia | 16 |
| United Kingdom | 15 |
| France | 14 |
| Italy | 13 |
| Canada | 11 |
| Germany | 11 |
| South Korea | 11 |
| Netherlands | 9 |
| Japan | 7 |
| Belgium | 5 |
| Taiwan | 5 |
| Brazil | 2 |
| Mexico | 2 |
| Norway | 2 |
| Poland | 2 |
| Sweden | 2 |
| Puerto Rico | 2 |
| Denmark | 2 |
| Singapore | 2 |
| Hong Kong | 2 |
| Ireland | 2 |
| Chile | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Flooring contractors in the United States](https://specstream.ai/data/businesses/flooring-contractors/united-states)
- [Building contractors in the United States](https://specstream.ai/data/businesses/building-contractors/united-states)
- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
- [Home inspectors in the United States](https://specstream.ai/data/businesses/home-inspectors/united-states)
- [Comfort food restaurants in the United States](https://specstream.ai/data/businesses/comfort-food-restaurants/united-states)
